Zoetis Inc. (NYSE:ZTS) Shares Sold by Kampmann Melissa S.

Kampmann Melissa S. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,085 shares of the company’s stock after selling 295 shares during the quarter. Zoetis makes up 2.5% of Kampmann Melissa S.’s portfolio, making the stock its 17th largest holding. Kampmann Melissa S.’s holdings in Zoetis were worth $3,482,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP lifted its position in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. Wallace Advisory Group LLC increased its stake in shares of Zoetis by 37.8% in the second quarter. Wallace Advisory Group LLC now owns 4,476 shares of the company’s stock valued at $776,000 after purchasing an additional 1,228 shares during the period. Wellington Wealth Strategies LLC. bought a new stake in shares of Zoetis during the second quarter valued at approximately $248,000. NewEdge Advisors LLC boosted its position in shares of Zoetis by 32.8% during the second quarter. NewEdge Advisors LLC now owns 35,192 shares of the company’s stock worth $6,101,000 after buying an additional 8,688 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Zoetis by 26.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 278,016 shares of the company’s stock worth $48,201,000 after buying an additional 57,902 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $194.81 on Monday. The company’s fifty day moving average is $186.04 and its two-hundred day moving average is $174.78. The company has a market cap of $88.26 billion, a P/E ratio of 37.54, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the business earned $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.